BriaCell (BCTX) Therapeutics will be highlighting its overall survival and clinical benefit data in metastatic breast cancer patients including those with CNS metastasis who were treated with the Bria ...

Post-approval overall survival data showed a significant benefit for 32% of the drugs evaluated. Most cancer drugs that have immature overall survival (OS) data when approved by the US Food and Drug ...

Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...

The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already ...

Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival ...

Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used with platinum-doublet chemotherapy ...

Please provide your email address to receive an email when new articles are posted on . The addition of anlotinib to standard of care for newly diagnosed glioblastoma significantly improved PFS in a ...

The median overall survival was 41.9 months in the cabozantinib arm and 42.0 months in the control arm. Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improves ...